Leading Medical Company Receives FDA Clearance For Obesity Drug Candidate
Groundbreaking Progress in Obesity Treatment: NeuroBo Pharmaceuticals Receives FDA Clearance for Clinical Trial of DA-1726.
In a significant milestone for obesity treatment, NeuroBo Pharmaceuticals, a leading pharmaceutical company, has received FDA clearance to commence a Phase 1 clinical trial for its new drug candidate, DA-1726. This marks a critical advancement in the medical field, with potential far-reaching implications for the millions of individuals struggling with obesity. $NeuroBo Pharmaceuticals(NRBO.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
